Hao Ede - Innovent Biologics CFO Director
| IVBXF Stock | USD 4.86 0.03 0.62% |
Insider
Hao Ede is CFO Director of Innovent Biologics
| Age | 64 |
| Phone | 86 512 6956 6088 |
| Web | https://www.innoventbio.com |
Innovent Biologics Management Efficiency
The company has return on total asset (ROA) of (0.1372) % which means that it has lost $0.1372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.287) %, meaning that it generated substantial loss on money invested by shareholders. Innovent Biologics' management efficiency ratios could be used to measure how well Innovent Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Cornelis Kruif | Merus BV | 59 | |
| BCh BM | Kronos Bio | 40 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Christian Davis | Telix Pharmaceuticals Limited | N/A | |
| Andy Porter | Relay Therapeutics | N/A | |
| MD MBA | MAIA Biotechnology | 54 | |
| Christopher MSc | Keros Therapeutics | 50 | |
| Prof MD | Lyell Immunopharma | N/A | |
| Sergei Gryaznov | MAIA Biotechnology | 64 | |
| Richard Compton | Oxford Nanopore Technologies | N/A | |
| Joseph McGuire | MAIA Biotechnology | 66 | |
| AGIA ACG | Telix Pharmaceuticals Limited | N/A | |
| Marni Kottle | Kronos Bio | N/A | |
| Keith MBA | Keros Therapeutics | 54 | |
| Alexis AM | Relay Therapeutics | 52 | |
| MA MBA | Relay Therapeutics | 48 | |
| Christopher Garcia | Arcus Biosciences | N/A | |
| Pr Bayley | Oxford Nanopore Technologies | N/A | |
| Shiniu Wei | Genscript Biotech | 44 | |
| Anna MBA | Mersana Therapeutics | 60 | |
| Sara Le | Oxford Nanopore Technologies | N/A | |
Management Performance
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 |
Innovent Biologics Leadership Team
Elected by the shareholders, the Innovent Biologics' board of directors comprises two types of representatives: Innovent Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovent. The board's role is to monitor Innovent Biologics' management team and ensure that shareholders' interests are well served. Innovent Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovent Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Min Liu, Chief Officer | ||
| Blake Salisbury, Sr Devel | ||
| Eduard MD, Pres USA | ||
| Yong MD, President | ||
| Vivian Zhang, Chief Officer | ||
| Dongming Wang, VP Quality | ||
| Changshou Gao, VP CTO | ||
| Yanju Wang, Joint Sec | ||
| Hao Ede, CFO Director | ||
| DeChao Yu, Chairman CoFounder |
Innovent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Innovent Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Shares Owned By Insiders | 7.15 % | |||
| Shares Owned By Institutions | 44.34 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.